EP0455719A4 - Composition and treatment with peptide combinations - Google Patents
Composition and treatment with peptide combinationsInfo
- Publication number
- EP0455719A4 EP0455719A4 EP19900902924 EP90902924A EP0455719A4 EP 0455719 A4 EP0455719 A4 EP 0455719A4 EP 19900902924 EP19900902924 EP 19900902924 EP 90902924 A EP90902924 A EP 90902924A EP 0455719 A4 EP0455719 A4 EP 0455719A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- peptide
- derivative
- analogue
- administered
- pgla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Definitions
- This invention relates to biologically active peptides, and more particularly to compositions and uses involving combinations of biologically active peptides.
- a composition which includes (a) a magainin peptide or analogue or derivative thereof; and (b) at least one member selected from the group consisting of (i) a PGLa peptide or analogue or derivative thereof and (ii) an XPF peptide or analogue or derivative thereof.
- the magainin peptide or analogue or derivative thereof, as well as the PGLa peptide or analogue or derivative thereof and the XPF peptide or analogue or derivative thereof may be amide terminated or carboxy- erminated.
- a process which comprises administering to a host both (a) a magainin peptide or analogue or derivative thereof and (b) at least one member selected from the group consisting of (i) an XPF peptide or analogue or derivative thereof and (ii) a PGLa peptide or analogue or derivative thereof.
- components (a) and (b) may be administered in separate compositions.
- components (a) and (b) may be administered in a single composition.
- components (a) and (b) may be administered in amounts effective to inhibit growth of a target.
- the target for example, may be bacteria, fungi, protozoa, virally infected cells, malignant cells, or sperm cells as compared to normal host cells.
- the synergism may be due to association of the peptides to a novel multimeric complex, such as a dimer, which possesses markedly increased membrane affinity for the target cells.
- the complex formed between the two peptides is believed to possess potent membrane disruptive properties. It is believed that the peptides have the capacity to organize within target cell membranes and to disturb cellular functions.
- the magainin peptide or analogue or derivative thereof is employed in a dosage of from about lmg to about lOOmg per kilogram of host weight, when administered systemically.
- the magainin peptide is used in a concentration of from about .05% to about .50%.
- the PGLa peptide or analogue or derivative thereof when administered systemically, is administered in a dosage of from about lmg to about lOOmg per kilogram of host weight. When administered topically, the PGLa peptide is administered in a concentration of from about 0.5% to about .50%.
- the XPF peptide or analogue or derivative thereof when administered systemically, is administered in a dosage of from about lmg to about lOOmg per kilogram of host weight. When administered topically, the XPF peptide or analogue or derivative thereof is administered in a concentration of from about .05% to about .50%.
- this combination of peptides in accordance with the present invention is effective as an antibiotic, and may be employed to inhibit, prevent or destroy the growth or proliferation of microbes, such as bacteria, fungi, viruses or the like. Similarly, such compositions may be employed as an anti-viral composition to inhibit, prevent or destroy the growth or proliferation of viruses.
- compositions may also be employed as a spermicide to inhibit, prevent or destroy the motility of sperm.
- compositions may also be employed as anti-tumor agents to inhibit the growth of or destroy tumors.
- compositions have a broad range of potent antibiotic activity against a plurality of microorganisms, including gram-positive and gram-negative bacteria, fungi, protozoa and the like. Such compositions may be employed for treating or controlling microbial infection caused by organisms which are sensitive to such composition.
- the treatment may comprise administering to a host organism or tissues acceptable to or affiliated with a microbial infection an anti-microbial amount of magainin peptide or analog or derivative thereof and of PGLa peptide or XPF peptide.
- the compositions may also be used as preservatives or sterilants for materials susceptible to microbial contamination.
- the magainin peptide may be, for example, a magainin such as magainin I, II or III.or an analogue or derivative thereof.
- the magainin peptides preferably include the following basic peptide structure X, description
- R, , is a hydrophobic amino acid
- R, 2 is a basic hydrophilic amino acid
- , is a hydrophobic, neutral hydrophilic or basic hydrophilic amino acid
- R,, and R, are hydrophobic or basic hydrophilic amino acids;
- R, 5 is glutamic or aspartic acid, or a hydrophobic or basic hydrophilic amino acid, and n is
- R, is a hydrophobic,or neutral hydrophilic amino acid
- R, is a hydrophobic amino acid
- R, 5 is glutamic acid or aspartic acid.
- the hydrophobic amino acids may be selected from the class consisting of Ala, Cys, Phe, Gly, lie, Leu, Met, Val, Trp, and Tyr.
- the neutral hydrophilic amino acids may be selected from the class consisting of Asn, Gin, Ser, and Thr.
- the basic hydrophilic amino acids may be selected from the class consisting of Lys, Arg, and His, and ornithine (0).
- the magainin peptides generally include at least seventeen amino acids and may also include up to forty amino acids. Accordingly, the hereinabove described basic peptide structure of a magainin peptide may include additional amino acids at the amino end or at the carboxyl end, or at both ends.
- a magainin peptide may include the following structure: -Y 12 -x 12 - where , 2 is the hereinabove described basic peptide structure and Y, delete is
- a magainin peptide may also have the following structure
- R.g is a basic hydrophilic amino acid or asparagine or glutamine.
- R,g " R i 7 where R, 7 is a neutral hydrophilic amino acid, a hydrophobic amino acid, or a basic hydrophilic amino acid.
- R, 7 is a neutral hydrophilic amino acid.
- a magainin peptide may also have the following structure: where 12 , Y 1 and Z, 2 are as previously defined and a is 0 or 1 and b is 0 or 1.
- the magainin peptides may also include the following basic peptide structure X, 3 :
- R "R ll”R 14a "R 12 "R ll “R ll “R 12 “R 13 “ ' w " ere i n H ,R 12' R 13' R 14' and R ⁇ a are amino acids as hereinabove described.
- the magainin peptide may also include the following structure X I 'Z T . wherein , is the hereinabove described basic peptide structure and Z, ⁇ is
- R ⁇ , ⁇ , 1 a , R I5 , R 16 , and R 1? are as hereinabove described, and n is 0 or 1, and each n may be the same or different.
- the magainin peptides generally include at least fourteen amino acids and may include up to forty amino acids.
- a magainin peptide preferably has 22 or 23 amino acids. Accordingly, the hereinabove described basic peptide structures of a magainin peptide may include additional amino acids at the amino end or at the carboxyl end, or at both ends.
- magainin peptides having the following primary sequence (expressed as a single letter code) as well as appropriate analogues and deriatives thereof:
- the peptide employed in conjunction with the magainin peptide is a PGLa peptide or an XPF peptide.
- a PGLa peptide is either PGLa or an analogue or derivative thereof.
- the PGLa peptides preferably include the following basic structure X.,:
- the PGLa peptides generally include at least seventeen amino acids and may include as many as forty amino acids. Accordingly, the hereinabove described basic peptide sturcture for a PGLa peptide may include additional amino acids at the amino end or at the carboxyl end or at both the amino and carboxyl end.
- a PGLa peptide may have the following sturcture:
- PGLa peptide may also have the following structure:
- a PGLa peptide may also have the following structure: ⁇ a 'X W (Z 14 J b where , 4 ; Y, 4 and Z, 4 are as previously defined, a is 0 or 1 and b is 0 or 1.
- An XPF peptide is either XPF or an analogue or derivative thereof.
- the XPF like peptides preferably include the following basis peptide structure X,lb, :
- the XPF peptides generally include at least nineteen amino acids and may include up to forty amino acids. Accordingly, the hereinabove described basic peptide structure of XPF may include additional amino acids at the amino end, or at the carboxyl end or at both the amino and carboxyl ends.
- an XPF peptide may include the following structure:
- An XPF peptide may include the follwing structure:
- X 16> Y ⁇ g and Z ⁇ g are as previously defined : a is 0 or 1 and b is 0 or 1.
- XPF or PGLa peptides which are characterized by the following primary amino acid sequence (single letter amino acid code); PGLa: GMASKAGAIAGKIAKVALKAL (NH £ ) XPF: GWASKIGQTLGKIAKVGLKELIQPK A review of XPF and PGLa can be found in Hoffman et al, EMBO J. 2:711-714, 1983; Andreu et al, J.
- EXAMPLE 1 About 10 bacteria/ml were added to a small volume of Luria broth. Magainin 2 (MGN2), PGLa peptide, or a mixture of MGN2 and PGLa in a 1:1 molar ratio was added to the broth in increasing concentration. The minimal inhibitory concentration (MIC), which inhibits microbial growth completely at 24 hours is noted below in Table 1.
- EXAMPLE 2 the concentration of S. aureus killed by 100 ⁇ g/ml of preparations of Magainin 2, PGLa, and a preparation of Magainin 2 and PGLa in a 1:1 molar ratio is noted. It was found that a 100 ⁇ g/ml preparation of Magainin 2 does not completely kill S. aureus at concentrations of bacteria at less than 10 bacterial/ml. Similar results were also obtained for PGLa. The 100 ⁇ g/ml preparation of the equimolar miture of Magainin 2 and PGLa, however, achieved complete killing of a concentration of 10 bacteria/ml. Thus, the equimolar mixture of Magainin 2 and PGLa achieved an increase in bactericidal potency over either peptide by greater than 10 .
- EXAMPLE 3 3 Approximately 10 S. aureus bacteria were added per/ml of Luria broth. Peptide preparations containing varying molar ratio amounts of PGLa to
- Magainin 2 (mole PGLa/mole MGN2) were added to the broths to increasing concentration of peptide
- peptide combinations in accordance with the present invention, may be employed for treating a wide variety of hosts.
- a host may be an animal, and such animal may be a human or non-human animal.
- the magainin peptide and the PGLa and/or XPF peptide may be employed together in a single composition, or in separate compositions.
- the magainin peptide and PGLa and/or XPF peptide may be employed in a wide variety of pharmaceutical compositions in combination with a non-toxic pharmaceutical carrier or vehicle such as a filler, non-toxic buffer, or physiological saline solution.
- a non-toxic pharmaceutical carrier or vehicle such as a filler, non-toxic buffer, or physiological saline solution.
- Such pharmaceutical compositions may be used topically or systemically and may be in any suitable form such as a liquid, solid, semi-solid, injectable solution, tablet, ointment, lotion, paste, capsule, or the like. It is also contemplated that the magainin peptide and the PGLa and/or XPF peptide may be delivered or administered in different forms.
- the magainin peptide and PGLa and/or XPF peptide may also be used in combination with adjuvants, protease inhibitors, or compatible drugs where such a combination is seen to be desirable or advantageous in controlling infection caused by harmful microorganisms including protozoa viruses, and the like.
- the ⁇ eptide(s) of the present invention may be administered to a host; in particular an animal, in an effective antibiotic and/or anti-tumor and/or anti-viral and/or anti-microbial and/or a spermicidal amount.
Abstract
A composition comprising a magainin peptide or an analogue or derivative thereof, and at least one member selected from the group consisting of a PGLa peptide or analogue or derivative thereof, and an XPF peptide or analogue or derivative thereof. The composition is employed as a pharmaceutical.
Description
■1 -
COMPOSITION AND TREATMENT WITH PEPTIDE COMBINATIONS
This invention relates to biologically active peptides, and more particularly to compositions and uses involving combinations of biologically active peptides.
In accordance with an aspect of the present invention, there is provided a composition which includes (a) a magainin peptide or analogue or derivative thereof; and (b) at least one member selected from the group consisting of (i) a PGLa peptide or analogue or derivative thereof and (ii) an XPF peptide or analogue or derivative thereof. The magainin peptide or analogue or derivative thereof, as well as the PGLa peptide or analogue or derivative thereof and the XPF peptide or analogue or derivative thereof, may be amide terminated or carboxy- erminated.
In accordance with another aspect of the present invention, there is provided a process which comprises administering to a host both (a) a magainin peptide or analogue or derivative thereof and (b) at least one member selected from the group consisting
of (i) an XPF peptide or analogue or derivative thereof and (ii) a PGLa peptide or analogue or derivative thereof. In one embodiment, components (a) and (b) may be administered in separate compositions. In another embodiment, components (a) and (b) may be administered in a single composition. In addition, components (a) and (b) may be administered in amounts effective to inhibit growth of a target.
Although the present invention is not to be limited by any theoretical reasoning, it is believed that the combination of the magainin peptide with the PGLa peptide or XPF peptide provides a synergistic effect in the inhibition of growth of a target. The target, for example, may be bacteria, fungi, protozoa, virally infected cells, malignant cells, or sperm cells as compared to normal host cells. The synergism may be due to association of the peptides to a novel multimeric complex, such as a dimer, which possesses markedly increased membrane affinity for the target cells. The complex formed between the two peptides is believed to possess potent membrane disruptive properties. It is believed that the peptides have the capacity to organize within target cell membranes and to disturb cellular functions.
In general, the magainin peptide or analogue or derivative thereof is employed in a dosage of from about lmg to about lOOmg per kilogram of host weight, when administered systemically. When administered topically, the magainin peptide is used in a concentration of from about .05% to about .50%.
The PGLa peptide or analogue or derivative thereof, when administered systemically, is administered in a dosage of from about lmg to about lOOmg per kilogram of host weight. When administered
topically, the PGLa peptide is administered in a concentration of from about 0.5% to about .50%. The XPF peptide or analogue or derivative thereof, when administered systemically, is administered in a dosage of from about lmg to about lOOmg per kilogram of host weight. When administered topically, the XPF peptide or analogue or derivative thereof is administered in a concentration of from about .05% to about .50%.
The use of this combination of peptides in accordance with the present invention is effective as an antibiotic, and may be employed to inhibit, prevent or destroy the growth or proliferation of microbes, such as bacteria, fungi, viruses or the like. Similarly, such compositions may be employed as an anti-viral composition to inhibit, prevent or destroy the growth or proliferation of viruses.
Such compositions may also be employed as a spermicide to inhibit, prevent or destroy the motility of sperm.
Such compositions may also be employed as anti-tumor agents to inhibit the growth of or destroy tumors.
The compositions have a broad range of potent antibiotic activity against a plurality of microorganisms, including gram-positive and gram-negative bacteria, fungi, protozoa and the like. Such compositions may be employed for treating or controlling microbial infection caused by organisms which are sensitive to such composition. The treatment may comprise administering to a host organism or tissues acceptable to or affiliated with a microbial infection an anti-microbial amount of magainin peptide or analog or derivative thereof and of PGLa peptide or XPF peptide.
The compositions may also be used as preservatives or sterilants for materials susceptible to microbial contamination.
The magainin peptide may be, for example, a magainin such as magainin I, II or III.or an analogue or derivative thereof. The magainin peptides preferably include the following basic peptide structure X,„
-- Ru -Rn - 12 -R13 -Rn -R - 12 -Rn -
R14 "R12 "Rll "Rll "RL1 "R14a "(R155n "R14a ~R14 " wherein R, , is a hydrophobic amino acid, R,2 is a basic hydrophilic amino acid; ,» is a hydrophobic, neutral hydrophilic or basic hydrophilic amino acid;
R,, and R,, are hydrophobic or basic hydrophilic amino acids; R,5 is glutamic or aspartic acid, or a hydrophobic or basic hydrophilic amino acid, and n is
0 or 1. In a preferred embodiment, R,, is a hydrophobic,or neutral hydrophilic amino acid, R,, is a hydrophobic amino acid, and R,5 is glutamic acid or aspartic acid.
The hydrophobic amino acids may be selected from the class consisting of Ala, Cys, Phe, Gly, lie, Leu, Met, Val, Trp, and Tyr. The neutral hydrophilic amino acids may be selected from the class consisting of Asn, Gin, Ser, and Thr. The basic hydrophilic amino acids may be selected from the class consisting of Lys, Arg, and His, and ornithine (0).
The magainin peptides generally include at least seventeen amino acids and may also include up to forty amino acids. Accordingly, the hereinabove described basic peptide structure of a magainin peptide may include additional amino acids at the amino end or at the carboxyl end, or at both ends.
Thus, for example, a magainin peptide may include the following structure:
-Y12 -x12- where ,2 is the hereinabove described basic peptide structure and Y,„ is
(i) R12
(ii) R14a - 12
(iii) Rn -R1 a -R12
(iv) R -Rn -R1 a -R12 wherein R,, , Rι2» R14 and Rι4a are as previously defined.
A magainin peptide may also have the following structure
-Y -7 Λ12 L wherin X,2 is as previously defined and Z,« is:
(i) R,g where R.g is a basic hydrophilic amino acid or asparagine or glutamine.
(ii) R,g "Ri7 where R,7 is a neutral hydrophilic amino acid, a hydrophobic amino acid, or a basic hydrophilic amino acid. Preferably R,7 is a neutral hydrophilic amino acid.
A magainin peptide may also have the following structure:
where 12, Y1 and Z,2 are as previously defined and a is 0 or 1 and b is 0 or 1.
The magainin peptides may also include the following basic peptide structure X,3:
"R "Rll"R14a"R12"Rll"Rll"R12"R13"
' w"erein H,R12'R13' R14' and Rι a are amino acids as hereinabove described.
The magainin peptide may also include the following structure XI 'ZT . wherein ,, is the hereinabove described basic peptide structure and Z,^ is
(Rll (Rll (Rll)n-(R1 a (R15)n-(R14a)n-(R14)n-(R16)n-
(R17)n wherein R^ , χ , 1 a, RI5, R16, and R1? are as hereinabove described, and n is 0 or 1, and each n may be the same or different.
The magainin peptides generally include at least fourteen amino acids and may include up to forty amino acids. A magainin peptide preferably has 22 or 23 amino acids. Accordingly, the hereinabove described basic peptide structures of a magainin peptide may include additional amino acids at the amino end or at the carboxyl end, or at both ends.
As representative examples of such magainin peptides, there may be mentioned peptides having the following primary sequence (expressed as a single letter code) as well as appropriate analogues and deriatives thereof:
(a) (NH£) GIGKFLHSAGKFGKAFVGEIMKS (OH) or (NH£) (Magainin I)
(b) (NH2) GIGKFLHSAKKFGKAFVGEIMNS (OH) or ( H2) (Magainin II)
(c) (NH2) GIGKFLHSA FGKAFVGEIMN (OH) or (NH£) (Magainin III)
The following are examples of peptide derivatives or analogs of the basic structure:
(d)(NH2) IGKFLHSAKKFGKAFVGEIMNS (OH) or (NH£) (e)(NH2) GKFLHSAKKFGKAFVGEIMNS (OH) or (NH£) (f)(NH2) KFLHSAKKFGKAFVGEIMNS (OH) or (NH£) Magainin peptides are described in Proc. Natl. Acad Sci. Vol 84 pp. 5449-53 (Aug. 87). The term "magainin peptides" as used herein refers to the basic magainin structure as well as derivatives and analogs thereof, including but not limited to the representative derivatives or analogs.
The peptide employed in conjunction with the magainin peptide is a PGLa peptide or an XPF peptide.
A PGLa peptide is either PGLa or an analogue or derivative thereof. The PGLa peptides preferably include the following basic structure X.,:
Rll "R17 "R12 "Rll "R14 "R14 "Rll " Rll "R14 "R12 "Rll "Rll "R12 "Rll " Rll "Rll 'R12 " where R,,, TJJ R14' anc R17 are as Prev °usly defined.
The PGLa peptides generally include at least seventeen amino acids and may include as many as forty amino acids. Accordingly, the hereinabove described basic peptide sturcture for a PGLa peptide may include additional amino acids at the amino end or at the carboxyl end or at both the amino and carboxyl end.
Thus, for example, a PGLa peptide may have the following sturcture:
"Y14 "X14" where Xl,14, is as previously defined and
Y14 is
(i) Rn;
(ii) R1 -Rn where R,, and R,4 are as previously defined. For example, a PGLa peptide may also have the following structure:
"X14 "Z14" where ,4 is as previously defined; and Z,4 is
(i) Rn; or
(ii) R,,-R,,, where R,, is as previously defined.
A PGLa peptide may also have the following structure: ι^a 'XW (Z14Jb where ,4; Y,4 and Z,4 are as previously defined, a is 0 or 1 and b is 0 or 1.
An XPF peptide is either XPF or an analogue or derivative thereof. The XPF like peptides preferably include the following basis peptide structure X,lb, :
R11"R17"R12"R11"R14"R18"R17" RH"R14"R12"R11"R11"R12" R11"R11'R11"R12"(R15VR11'" ' wherein R,,, R]?' ^14» ^15 an< Ri7 are as previously defined and R,g is glutamine or asparagine, or a basic hydrophilic, or hydrophobic amino acid, and n is 0 or 1.
The XPF peptides generally include at least nineteen amino acids and may include up to forty amino acids. Accordingly, the hereinabove described basic peptide structure of XPF may include additional amino acids at the amino end, or at the carboxyl end or at both the amino and carboxyl ends.
Thus, for example, an XPF peptide may include the following structure:
"Y16 ~X16~ where X,g is as previously defined and Y,fi is
(i) Rn or
(ii) R -RU where R,, and R,4 are as previously defined.
An XPF peptide may include the follwing structure:
is
where X16> Y^g and Z^g are as previously defined : a is 0 or 1 and b is 0 or 1.
Preferred are XPF or PGLa peptides, which are characterized by the following primary amino acid sequence (single letter amino acid code); PGLa: GMASKAGAIAGKIAKVALKAL (NH£) XPF: GWASKIGQTLGKIAKVGLKELIQPK A review of XPF and PGLa can be found in Hoffman et al, EMBO J. 2:711-714, 1983; Andreu et al, J.
Biochem. 149:531-535, 1985; Gibson et al J. Biol.
Chem. 261:5341-5349, 1986; and Giovanni et al,
Biochem J. 241:113-120, 1987.
The present invention will be further described with respect to the following examples, however, the scope of the present invention is not to be limited thereby.
EXAMPLE 1 About 10 bacteria/ml were added to a small volume of Luria broth. Magainin 2 (MGN2), PGLa peptide, or a mixture of MGN2 and PGLa in a 1:1 molar ratio was added to the broth in increasing concentration. The minimal inhibitory concentration (MIC), which inhibits microbial growth completely at 24 hours is noted below in Table 1.
TABLE 1
ANTIBACTERIAL ACTIVITY OF COMBINATION OF PGLa AND MAGAININ 2
ORGANISM MINIMAL INHIBITORY CONCENTRATION fue/ml) MGN2 PGLa PGLa/MGN2
(1:1 molar ratio)
The above results indicate an increase in antibacterial activity when a combination of Magainin 2 and PGLa peptides is added to a culture broth of bacteria in a 1:1 molar ratio of Magainin 2 to PGLa over either peptide added alone.
EXAMPLE 2 In this example, the concentration of S. aureus killed by 100 μg/ml of preparations of Magainin 2, PGLa, and a preparation of Magainin 2 and PGLa in a 1:1 molar ratio is noted. It was found that a 100 μg/ml preparation of Magainin 2 does not completely kill S. aureus at concentrations of bacteria at less than 10 bacterial/ml. Similar results were also obtained for PGLa. The 100 μg/ml preparation of the equimolar miture of Magainin 2 and PGLa, however, achieved complete killing of a concentration of 10 bacteria/ml. Thus, the equimolar mixture of Magainin
2 and PGLa achieved an increase in bactericidal potency over either peptide by greater than 10 .
EXAMPLE 3 3 Approximately 10 S. aureus bacteria were added per/ml of Luria broth. Peptide preparations containing varying molar ratio amounts of PGLa to
Magainin 2 (mole PGLa/mole MGN2) were added to the broths to increasing concentration of peptide
(μg/ml). The microbial inhibitory concentration
(MIC), at which point no growth was evident after 24 hours was measured for each peptide preparation. The results are given in Table 2 below.
The above results indicate that maximum bactericidal activity is achieved when an equimolar mixture of PGLa and Magainin 2 is added to the S. aureus culture. It is also shown, however, that preparations containing both peptides in any molar ratio achieved greater bactericidal activity than either peptide alone.
The peptide combinations, in accordance with the present invention, may be employed for treating a
wide variety of hosts. In accordance with a preferred embodiment, a host may be an animal, and such animal may be a human or non-human animal. The magainin peptide and the PGLa and/or XPF peptide may be employed together in a single composition, or in separate compositions.
The magainin peptide and PGLa and/or XPF peptide may be employed in a wide variety of pharmaceutical compositions in combination with a non-toxic pharmaceutical carrier or vehicle such as a filler, non-toxic buffer, or physiological saline solution. Such pharmaceutical compositions may be used topically or systemically and may be in any suitable form such as a liquid, solid, semi-solid, injectable solution, tablet, ointment, lotion, paste, capsule, or the like. It is also contemplated that the magainin peptide and the PGLa and/or XPF peptide may be delivered or administered in different forms. The magainin peptide and PGLa and/or XPF peptide may also be used in combination with adjuvants, protease inhibitors, or compatible drugs where such a combination is seen to be desirable or advantageous in controlling infection caused by harmful microorganisms including protozoa viruses, and the like.
The ρeptide(s) of the present invention may be administered to a host; in particular an animal, in an effective antibiotic and/or anti-tumor and/or anti-viral and/or anti-microbial and/or a spermicidal amount.
Numerous modifications and variations of the present invention are possible in light of the above teachings, and, therefore, within the scope of the accompanying claims, the invention may be practiced other than as particularly described.
Claims
WHAT IS CLAIMED IS:
1. A composition comprising:
(a) a magainin peptide or analogue or derivative thereof; and
(b) at least one member selected from the group consisting of (i) a PGLa peptide or analogue or derivative thereof and (ii) an XPF peptide or analogue or derivative thereof.
2. The composition of Claim 1 wherein components (a) and (b) are present in an amount to inhibit growth of a target cell.
3. The composition of Claim 1 wherein component (b) is a PGLa peptide or analogue or derivative^ thereof.
4. The composition of Claim 1 wherein component (b) is an XPF peptide or analogue or derivative thereof.
5. A process, comprising: administering to a host both (a) a magainin peptide or analogue or derivative thereof and (b) at least one member selected from the group consisting of (i) an XPF peptide or analogue or derivative thereof and (ii) a PGLa peptide or analogue or derivative thereof.
6. The process of Claim 5 wherein components
(a) and (b) are administered in separate compositions.
7. The the process of Claim 5 wherein (a) and
(b) are administered in a single composition.
8. The process of Claim 5 wherein (a) and (b) are administered in amounts effective to inhibit growth of a target.
9. The process of Claim 8 wherein the magainin peptide or analogue or derivative thereof is administered systemically.
10. The process of Claim 9 wherein the magainin peptide or analogue or derivative thereof is administered in an amount of from about lmg to about lOOmg per kilogram of host body weight.
11. The process of Claim 8 wherein the magainin peptide or analogue or derivative thereof is administered topically.
12. The process of Claim 11 wherein the magainin peptide or analogue or derivative thereof is administered in a concentration of from about .05% to about .50%.
13. The process of Claim 8 wherein component (b) is a PGLa peptide or analogue or derivative thereof.
14. The process of Claim 13 wherein the PGLa peptide or analogue or derivative thereof is administered systemically.
15. The process of Claim 14 wherein the PGLa peptide or analogue or derivative thereof is administered in an amount of from about lmg to about - lOOmg per kilogram of host body weight.
16. The process of Claim 13 wherein the PGLa peptide or analogue or derivative thereof is administered topically.
17. The process of Claim 16 wherein the PGLa peptide or analogue or derivative thereof is administered in a concentration of from about .05% to about .50%.
18. The process of Claim 8 wherein component (b) is an XPF peptide or analogue or derivative thereo .
19. The process of Claim 18 wherein the XPF peptide is administered systemically.
20. The process of Claim 1? wherein the XPF peptide or analogue or derivative thereof is
administered in an amount of from about lmg to about lOOmg per kilogram of host body weight.
21. The process of Claim 18 wherein the XPF peptide or analogue or derivative thereof is administered topically.
22. The process of Claim 21 wherein the XPF peptide or analogue or derivative thereof is administered in a concentration of from about .05% to about .50%.
23. The process of Claim 8 wherein said target is a bacterium.
24. The process of Claim 8 wherein said target is a fungus.
25. The process of Claim 8 wherein said target s a protozoan.
26. The process of Claim 7 wherein said target s a tumor cell.
27. The process of Claim 8 wherein said target s a virally-infected cell.
28. The process of Claim 8 wherein said target s a sperm cell.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30298589A | 1989-01-30 | 1989-01-30 | |
| US302985 | 1989-01-30 | ||
| US34689489A | 1989-05-03 | 1989-05-03 | |
| US346894 | 1989-05-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0455719A1 EP0455719A1 (en) | 1991-11-13 |
| EP0455719A4 true EP0455719A4 (en) | 1992-07-08 |
Family
ID=26973198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19900902924 Withdrawn EP0455719A4 (en) | 1989-01-30 | 1990-01-25 | Composition and treatment with peptide combinations |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0455719A4 (en) |
| JP (1) | JPH04506056A (en) |
| AU (1) | AU5042890A (en) |
| CA (1) | CA2007913A1 (en) |
| WO (1) | WO1990008552A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU648140B2 (en) * | 1991-02-01 | 1994-04-14 | Virtual Drug Development, Inc. | Reverse antimicrobial peptides and antimicrobial compositions |
| EP0590044A4 (en) * | 1991-06-12 | 1996-06-12 | Magainin Pharma | Composition and treatment with biologically active peptides having c-terminal substitutions |
| US5593866A (en) * | 1992-08-21 | 1997-01-14 | The University Of British Columbia | Cationic peptides and method for production |
| US6057291A (en) | 1995-06-02 | 2000-05-02 | University Of British Columbia | Antimicrobial cationic peptides |
| ATE412668T1 (en) | 1995-08-23 | 2008-11-15 | Univ British Columbia | ANTIMICROBIAL CATIONIC PEPTIDES AND METHODS FOR THEIR IDENTIFICATION |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988006597A1 (en) * | 1987-03-04 | 1988-09-07 | The United States Of America, As Represented By Th | New synthetic bioactive compounds and method of producing bioactive effect |
-
1990
- 1990-01-17 CA CA002007913A patent/CA2007913A1/en not_active Abandoned
- 1990-01-25 JP JP2503427A patent/JPH04506056A/en active Pending
- 1990-01-25 EP EP19900902924 patent/EP0455719A4/en not_active Withdrawn
- 1990-01-25 AU AU50428/90A patent/AU5042890A/en not_active Abandoned
- 1990-01-25 WO PCT/US1990/000460 patent/WO1990008552A1/en not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988006597A1 (en) * | 1987-03-04 | 1988-09-07 | The United States Of America, As Represented By Th | New synthetic bioactive compounds and method of producing bioactive effect |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO9008552A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2007913A1 (en) | 1990-07-30 |
| JPH04506056A (en) | 1992-10-22 |
| EP0455719A1 (en) | 1991-11-13 |
| AU5042890A (en) | 1990-08-24 |
| WO1990008552A1 (en) | 1990-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0750506B1 (en) | Broad spectrum antimicrobial compounds and methods of use | |
| US5221664A (en) | Composition and treatment with biologically active peptides and toxic cations | |
| US7354903B2 (en) | Cosmetic compositions containing short bioactive peptides | |
| KR101700603B1 (en) | An anti-microbial peptide, Periplanetasin-1 isolated from Periplaneta americana and its synthetic composition | |
| US5217956A (en) | Composition and treatment with biologically active peptides and certain anions | |
| US5073542A (en) | CPF peptide compositions and their use in inhibiting growth of target cells or a virus | |
| US5235038A (en) | Deletion and substitution analogues of melittin peptide | |
| US5208220A (en) | Composition and treatment with biologically active peptides and antibiotics which inhibit DNA gyrase | |
| KR20170053877A (en) | An anti-microbial peptide, Oxyasin-2 isolated from Oxya chinensis sinuosa and its synthetic composition | |
| KR20170053879A (en) | An anti-microbial peptide, Oxyasin-1 isolated from Oxya chinensis sinuosa and its synthetic composition | |
| AU641129B2 (en) | Composition and treatment with biologically active peptides and certain anions | |
| EP0455719A4 (en) | Composition and treatment with peptide combinations | |
| US5254537A (en) | Composition and treatment with peptide combinations | |
| WO1989011290A1 (en) | Amphiphilic peptides and use thereof | |
| KR20180117793A (en) | An anti-microbial peptide, Teleogryllusine 2 isolated from Teleogryllus emma and its synthetic composition | |
| EP0440688B1 (en) | Cpf peptide compositions and uses | |
| CA2040510A1 (en) | Composition and treatment with biologically active peptides and toxic cations | |
| CN111228462A (en) | Antimicrobial peptide preparation and preparation method thereof | |
| KR101851134B1 (en) | An anti-microbial peptide, Periplanetasin-6 isolated from Periplaneta americana and its synthetic composition | |
| EP0533795A1 (en) | Composition of and treatment with biologically active peptides having d-amino acid residues | |
| EP0526570A4 (en) | Composition and treatment with biologically active peptides and anti-parasitic agents or anti-fungal agents | |
| KR20170131898A (en) | An anti-microbial peptide, Oxyasin-4 isolated from Oxya chinensis sinuosa and its synthetic composition | |
| KR101889403B1 (en) | An anti-microbial peptide, Periplanetasin-4 isolated from Periplaneta americana and its synthetic composition | |
| WO1992000090A1 (en) | Composition and treatment with biologically active peptides and antibiotics which inhibit dna gyrase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19910529 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK FR GB IT LI LU NL SE |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 19920514 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK FR GB IT LI LU NL SE |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
|
| 17Q | First examination report despatched |
Effective date: 19940627 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19951201 |